Author: biocytogen

RenMab™ Mouse Featured in GEN Magazine

November 8, 2019

Biocytogen’s RenMab™ Mouse is featured in the Nov. Issue of Genetic Engineering & Biotechnology News (GEN). Read the full article here.  RenMab™ Mouse highlights: Developed upon Biocytogen’s unique Mb-scale chromosome engineering technology Variable regions of heavy chain and k light chain are replaced by human counterparts in situ Constant region is retained to ensure proper B […]

Read More

Biocytogen’s RenMab™ Mouse is Featured on Fiercebiotech

October 28, 2019

Biocytogen’s RenMab™ Mouse is featured on Fiercebiotech.com today. Read the full article here.  RenMab™ Mouse highlights: Developed upon Biocytogen’s unique Mb-scale chromosome engineering technology Variable regions of heavy chain and k light chain are replaced by human counterparts in situ Constant region is retained to ensure proper B cell development Normal response to immunization FierceBiotech and […]

Read More

Festival of Biologics 2019

October 7, 2019

Location: Basel Congress Centre, Basel, Switzerland Dates: October 15-17, 2019 Booth: 27 Presentation Title: Accelerating Therapeutic Antibody Discovery with Fully Human Antibody (RenMab™) Mice and Target Humanized Animal Models Speaker: Gary Ng, Marketing Manager, Biocytogen Time: Wednesday, October 16th, 3:15 – 3:35pm Presentation Session: Bispecifics development Presentation Abstract: Biocytogen has recently developed RenMab™ Mouse, a […]

Read More

Novel Antibody Therapeutics Congress

October 7, 2019

Location: London Heathrow Marriott Hotel, Bath Road, Harlington, Hayes, United Kingdom Dates: October 10-11, 2019 Booth: Ex-24 Presentation Title: Accelerating Therapeutic Antibody Discovery with Fully Human Antibody (RenMab™) Mice and Target Humanized Animal Models Speaker: Benny Yang, Ph.D., Chief Scientific Officer & Director of Antibody Discovery, Biocytogen Time: Thursday, October 10th, 10:20-10:50am Presentation Abstract: Biocytogen […]

Read More

2nd Annual Advances in Immuno-Oncology USA Congress

October 2, 2019

Location: DoubleTree by Hilton Hotel San Diego, Mission Valley, USA Dates: October 8-9, 2019 Booth: #4 Presentation Title: Accelerating Therapeutic Antibody Discovery with Fully Human Antibody (RenMab™) Mice and Target Humanized Animal Models Speaker: Chaoshe Guo, Ph.D., M.D., Vice President & Global Head of Business Development of Biocytogen Time: Tuesday, Oct. 8th, 1:50-2:20pm Session: Translational […]

Read More

Experts in Genetically Engineered Animal Development and Maintenance

September 11, 2019

Time: 10:30-11:30am, Sept. 19th, 2019 Location: Conference Room D1, Building 114, Massachusetts General Hospital, 16th Street, Charlestown MA  02129 Speakers: Daniel Trombly, Ph.D. Gene Editing Specialist, Biocytogen Boston Corporation Christopher Dowdy, Ph.D. Client & Scientific Portfolio Manager Research Models and Services, Charles River Laboratories

Read More

2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

August 30, 2019

Location: Hilton Garden Inn Philadelphia Center City Dates: Sept. 19-20, 2019 Booth: #Ex-7 Presentation Title: Accelerating Therapeutic Antibody Discovery and Development with Innovative Humanized Mouse Models Time: 10:05 AM, Sept. 19, 2019 Location: Stream B – Immune Checkpoint Inhibitors & Combination Strategies Presentation Abstract: The talk will present you Biocytogen services for your antibody discovery […]

Read More

Biocytogen Closes $79M Series D Funding

August 9, 2019

On August 2019, Beijing Biocytogen Co., Ltd. (“Biocytogen”) announced the closing of its Series D funding of $79M (RMB 543M). This round of financing was jointly led by  investment giants China Life Healthcare Fund and SDIC Venture Capital Co., Ltd., and has demostrated continued participation from Series C investors CMB International and 3E Bioventures. Biocytogen […]

Read More

American Association for Cancer Research (AACR) Annual Meeting 2019

Date: March 29 - April 3, 2019
Location: Atlanta, Georgia

Biocytogen Highlights 10 Posters highlight new IO targets (e.g. CTLA-4, OX40, CD3e), preclinical services, PK/PD studies, and antibody screening platform will be presented at AACR. Time Abstract Full Name Abstract # Board # Category Apr 1 8AM – 12PM Anti-SIRPα antibodies as a   potential weapon for cancer immunotherapy via accelerated screening in   humanized […]

Read More

Back to top